PRESS-RELEASE ·Filed May 7, 2026

CELC

Celcuity Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

This is a routine earnings date announcement with no new financial information. The stock's recent strong rally on clinical momentum (VIKTORIA-1/2 trials) suggests the May 14 earnings call will be closely watched for pipeline updates and cash runway. Monitor for any pre-announcement or data readout before the call.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CELC ▼ -32.89% at T+60d
NEUTRAL call ✗ call lost -32.89% · α vs SPY -36.72% · entry $130.71 → $87.72
Entry anchored
May 7, 04:49 AM ET
via exchange tick
T+1d
+0.27%
call +0.27% · α -0.56%
$131.06
settled 5mo ago
T+5d
-4.77%
call -4.77% · α -6.28%
$124.47
settled 5mo ago
T+20d
-31.95%
call -31.95% · α -35.08%
$88.95
settled 4mo ago
T+60d
-32.89%
call -32.89% · α -36.72%
$87.72
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Celcuity announced it will release Q1 2026 financial results on May 14, 2026, after market close. The press release contains no financial data for the current period; it only provides logistics for the earnings call. The most recent reported quarter (Q4 2025) showed an EPS miss of -9.0% versus consensus, but the stock has rallied significantly on prior neutral filings, suggesting strong investor sentiment tied to clinical pipeline progress.

Key Facts

  • Q1 2026 earnings release scheduled for May 14, 2026 after market close
  • Conference call at 4:30 PM ET on same day
  • No financial results or guidance provided in this press release
  • Prior quarter (Q4 2025) EPS of -$0.97 missed consensus of -$0.89 by 9.0%
  • Stock has rallied +28.65% over 20 days following the prior neutral filing
  • Market cap is $6.7B with 89% analyst buy rating

Financial Impact

No financial data in this filing; prior quarter EPS miss of 9%

Risk Factors

  • No financial data in this filing — all materiality deferred to May 14 release
  • Prior quarter EPS miss of 9% may indicate continued cash burn without revenue
  • Stock at $6.7B market cap with no approved products — binary clinical risk

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289927
15 reports for CELC
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+20▲ +26.84%Jun 11, 2026
Filters
Rows
Reports for CELC — sortable, filterable
TypeNow
Aug 26, 2026
5w ago
8-K
BULLISH ★ 7/10
$95.08 $84.00▼ −11.65%▼ −12.86%$72.51 (−23.74%)
Jul 15, 2026
11w ago
144
BEARISH ★ 6/10
$91.51 $92.08▼ −0.62%▲ +1.72%$72.51 (+20.76%)
Jul 14, 2026
11w ago
Press Release
BULLISH ★ 8/10
$91.51 $92.08▲ +0.62%▼ −1.72%$72.51 (−20.76%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 5/10
$89.49 $113.51▲ +26.84%▲ +24.95%$72.51 (−18.97%)
Jun 8, 2026
16w ago
8-K
MIXED ★ 6/10
$92.59 $115.72▲ +24.98%▲ +23.53%$72.51 (−21.69%)
Jun 5, 2026
17w ago
424B5
MIXED ★ 6/10
$88.28 $108.58▲ +23.00%▲ +21.13%$72.51 (−17.86%)
Jun 4, 2026
17w ago
Press Release
MIXED ★ 6/10
$92.47 $107.95▲ +16.74%▲ +18.11%$72.51 (−21.59%)
Jun 3, 2026
17w ago
Press Release
BEARISH ★ 6/10
$88.95 $107.95▼ −21.36%▼ −22.36%$72.51 (+18.48%)
Jun 3, 2026
17w ago
424B5
BEARISH ★ 6/10
$88.95 $107.95▼ −21.36%▼ −22.36%$72.51 (+18.48%)
Jun 2, 2026
17w ago
8-K
BULLISH ★ 8/10
$91.42 $104.49▲ +14.30%▲ +15.86%$72.51 (−20.68%)
Showing 10 of 15

US Market Status

Market Open — Closes in 2h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 7, 2026